Epirubicin

KRAS G12C

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Phase 1Active

CC

41/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 81/ 100

Competitive context

23 Active assets in the KRAS G12C cohort.

Asset / Sponsor	Phase	Rating
Sotorasib ETOP IBCSG Partners Foundation	Phase 2	CCC
Adagrasib Ryan Gentzler, MD	Phase 2	CCC
LENVATINIB ETOP IBCSG Partners Foundation	Phase 2	CCC
Opnurasib Maastricht University Medical Center	Phase 2	CCC
Fulzerasib Innovent Biologics (Suzhou) Co. Ltd.	Phase 1/2	CCC

View all 23 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant

BBB

Indicative ·

74 / 100

Lung Non-Small Cell Squamous CarcinomaDormant

BBB

Indicative ·

72 / 100

Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant

BBB

Indicative ·

72 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.